



BIOMM S.A.

Public Listed Company

Corporate Tax Payer's ID (CNPJ/MF) nº 04.752.991/0001-10

NIRE nº 31.300.016.510

MATERIAL FACT

BIOMM S.A. ("Company" or "Biommm"), in compliance with the provisions of CVM Instruction No. 358 of January 3rd, 2002, as amended, hereby informs its shareholders and the market in general that, as of today, it has been published by ANVISA, through the Biologic Medicines and Products General Management, the resolution - RE nº 1.792, of 5th of July of 2018, in the Official Gazette of the Union, granting the registration Biommm's insulin glargine, Glargilin®.

Insulin glargine is a long-acting analogous insulin, considered to be an improvement over NPH human insulin because of its action profile of a lower risk of hypoglycemia.

Subsequently to the registration, the Company, exclusive supplier and distributor of Glargilin® in Brazil, will request product price authorization to the CMED (Câmara de Regulação de Mercado de Medicamentos).

It is important to highlight that, this approval allow Biommm to offer treatment option to millions of diabetic patients, either in pharmacies or in the public sector; and especially through the Productive Development Partnership ("PDP") approved by the Ministry of Health, in which the Company will be responsible for the supply of 100% (one hundred percent) of insulin glargine demand, within PDP request, in partnership with Fundação Ezequiel Dias - FUNED.

The Company will maintain its shareholders and the market updated on the subject of this material fact.

Nova Lima, 9th of July of 2018.

Douglas de Carvalho Lopes

IR Director